- Home
- WOW vs ATXS Comparison
WOW vs ATXS Comparison
Compare WOW & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOW
- ATXS
- Stock Information
- Founded
- WOW 2001
- ATXS 2008
- Country
- WOW United States
- ATXS United States
- Employees
- WOW N/A
- ATXS N/A
- Industry
- WOW Cable & Other Pay Television Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- WOW Telecommunications
- ATXS Health Care
- Exchange
- WOW Nasdaq
- ATXS Nasdaq
- Market Cap
- WOW 440.8M
- ATXS 424.4M
- IPO Year
- WOW 2017
- ATXS 2015
- Fundamental
- Price
- WOW $5.15
- ATXS $7.43
- Analyst Decision
- WOW Hold
- ATXS Buy
- Analyst Count
- WOW 2
- ATXS 6
- Target Price
- WOW $5.20
- ATXS $32.00
- AVG Volume (30 Days)
- WOW 757.8K
- ATXS 313.6K
- Earning Date
- WOW 11-03-2025
- ATXS 11-12-2025
- Dividend Yield
- WOW N/A
- ATXS N/A
- EPS Growth
- WOW N/A
- ATXS N/A
- EPS
- WOW N/A
- ATXS N/A
- Revenue
- WOW $604,800,000.00
- ATXS N/A
- Revenue This Year
- WOW N/A
- ATXS N/A
- Revenue Next Year
- WOW N/A
- ATXS N/A
- P/E Ratio
- WOW N/A
- ATXS N/A
- Revenue Growth
- WOW N/A
- ATXS N/A
- 52 Week Low
- WOW $3.06
- ATXS $3.56
- 52 Week High
- WOW $5.78
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- WOW 77.89
- ATXS 58.46
- Support Level
- WOW $5.06
- ATXS $7.12
- Resistance Level
- WOW $5.15
- ATXS $7.91
- Average True Range (ATR)
- WOW 0.02
- ATXS 0.46
- MACD
- WOW -0.04
- ATXS 0.09
- Stochastic Oscillator
- WOW 94.44
- ATXS 72.63
About WOW WideOpenWest Inc.
WideOpenWest Inc is a cable operator and broadband service, provider. The company serves residential, business and wholesale customers in Illinois, Michigan, Indiana, Ohio, Kansas, Tennessee, Maryland, and South Carolina. Its service portfolio consists of high-speed internet, data, voice, cloud, and cable television services. The company operates in one business segment that is Broadband Services. The majority of the revenue is generated from the subscription service revenue received.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.